title: [Surrogate end points as a clinical and public health problem. The cerivastatin case].
authors.affiliation: Médico general, Canencia de la Sierra, Madrid, Spain. jgervasc@meditex.es
authors.forename: Juan
authors.initials: J
authors.lastname: Gérvas
authors.forename: Mercedes
authors.initials: M
authors.lastname: Pérez Fernández
mesh_terms: D015415:Biomarkers; D002986:Clinical Trials as Topic; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000009:adverse effects / Q000627:therapeutic use*; D012306:Risk; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011725:Pyridines; C086276:cerivastatin